EuroPCR 2022 | Changes in Cardiac Damage after Surgical Aortic Valve Replacement

This study presented at EuroPCR 2022 analyzed the PARTNER study pool and included 1974 patients with a complete echocardiogram.

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico  por cirugía

Surgical risk was 17.3% extreme/inoperable, 54.3% intermediate and 28.4% low.

60% received transcatheter aortic valve replacement (TAVR) and the rest surgical aortic valve replacement (SAVR). 

6.1% of patients were in stage 0 (no damage), 14.5% were in stage 1 (left ventricular damage), 51.4% in study 2 (mitral or left ventricular damage), 20.9% in stage 3 (pulmonary vascular or tricuspid damage) and 7.1% were in stage 4 (right ventricular damage).

Baseline damage was associated with mortality at 2 years with both strategies, as was the composite of death and rehospitalization for cardiac failure. This was maintained after adjusting for variables at one-year followup. 

Cardiac damage remained unchanged in 60% of patients and worsen in 25%. 

At 2 years, morality for stages 0, 1, 2 ,3 and 4 was 2.5%, 7.1%, 14.6%, 28,2% and 28.2% respectively; and for mortality and rehospitalization for cardiac failure, it was 4.1% (stage 0), 13.4% (stage 1), 22.9% (stage 2), 38.7% (stage 3) and 39% (stage 4).

Read also: Should Total Occlusion Influence on Revascularization Strategy?

Improved myocardial damage was associated with lower mortality and rehospitalization for cardiac failure, and worse myocardial damage increased these events. 

Independent predictors of stage worsening were hypertension (OR 1.73; 95% CI 1.01-2.96) and SAVR (OR 2.04; 95% CI 1.52-2.74).

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Source: TCTmd.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...